Avon Products, Inc. (NYSE:AVP)’s shares increased 1.39% to $9.46. The company on Dec. 17 announced that the company has entered into agreements with the U.S. Department of Justice (DOJ) and the Securities and Exchange Commission (SEC) related to the previously disclosed Foreign Corrupt Practices Act (FCPA) investigations. The terms of agreements are in line with the expected terms the company previously reported.
Should Investors Buy AVP After The Recent Development? Find Out Here
The agreements include aggregate payments of $135 million to the two U.S. government agencies, with $68 million in fines payable to the DOJ and $67 million in disgorgement and prejudgment interest payable to the SEC, in connection with charges that the company violated the books and records and internal controls provisions of the FCPA.
OvaScience Inc(NASDAQ:OVAS)’s shares surged 23.63% to $43.22. The company on Dec. 17 announced the Company has achieved its 2014 corporate goals to advance the AUGMENTSM, OvaPrimeSM and OvaTureSM treatments for patients in need of new fertility treatment options.
Is OVAS Going To Rise or Fall After Today’s Price Action? Find Out Here
“We are pleased to report that we have successfully matured human egg precursor cells into eggs in vitro. This is a major milestone for the first potential hormone-free fertility option, the OvaTure treatment. We have achieved this by designing an autologous, high throughput in vitro system, which we believe will accelerate further development of the OvaTure treatment, the only hormone-free fertility option,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience.
AgenusInc (NASDAQ:AGEN)’s shares jumped 17.16% to $3.92. The company on Dec. 18 announced that its partner GlaxoSmithKline (GSK) reported that the ZOE-50 Phase 3 study met its primary endpoint. Analysis of the primary endpoint showed that HZ/su reduced the risk of shingles by 97.2 per cent in adults aged 50 years and older compared to placebo. HZ/su is a novel candidate vaccine that combines gE, a protein found on the varicella-zoster virus that causes shingles, with GSK’s Adjuvant System, AS01B, which serves to stimulate a stronger immunological response to the vaccine.
Can Traders Buy AGEN After The Solid Rally? Get Free Trend Analysis Here
About thenextbigtrade.com
thenextbigtrade.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. thenextbigtrade.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed “informational edge” which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at Specialpennystockalert.com.
Disclaimer
The assembled information disseminated by thenextbigtrade.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. thenextbigtrade.com does expect that investors will buy and sell securities based on information assembled and presented in thenextbigtrade.com. PLEASE always do your own due diligence, and consult your financial advisor.
]]>